Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung

• Published in: Journal of cancer research and clinical oncology Vol. 147; no. 12; pp. 3709 - 3718
• Main Authors: Ueda, Daisuke, Ito, Masaoki, Tsutani, Yasuhiro, Giménez-Capitán, Ana, Román-Lladó, Ruth, Pérez-Rosado, Ana, Aguado, Cristina, Kushitani, Kei, Miyata, Yoshihiro, Arihiro, Koji, Molina-Vila, Miguel Angel, Rosell, Rafael, Takeshima, Yukio, Okada, Morihito
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2021; Springer Nature B.V
• Subjects: Adenocarcinoma; Cancer; Cancer Research; Computed tomography; Genetic diversity; Hematology; Immunohistochemistry; Internal Medicine; Lung cancer; Medical prognosis; Medicine; Medicine & Public Health; Multivariate analysis; Mutation; Oncology; Original Article – Clinical Oncology; PD-L1 protein; Polymerase chain reaction; Prognosis; Survival; PD-L1; Mucinous adenocarcinoma; nCounter; KRAS; NRG1
• DOI: 10.1007/s00432-021-03609-3
• ISSN: 0171-5216

Purpose The clinicopathological or genetic features related to the prognosis of mucinous adenocarcinoma are unknown because of its rarity. The clinicopathological or targetable features were investigated for better management of patients with mucinous adenocarcinoma of the lung. Methods We comprehensively evaluated the clinicopathological and genetic features of 60 completely resected mucinous lung adenocarcinomas. Targetable genetic variants were explored using nCounter and polymerase chain reaction, PD-L1 and TTF-1 expression were evaluated using immunohistochemistry. We analyzed the prognostic impact using the Kaplan–Meier method and log-rank test. Results Of the 60 enrolled patients, 13 (21.7%) had adenocarcinoma in situ/minimally invasive adenocarcinoma, and 47 (78.3%) had invasive mucinous adenocarcinoma (IMA). Fifteen patients (25%) showed a pneumonic appearance on computed tomography (CT). CD74-NRG1 fusion, EGFR mutations, and BRAF mutation were detected in three (5%), four (6.7%), and one (1.7%) patient(s), respectively. KRAS mutations were detected in 31 patients (51.7%). Two patients (3.5%) showed immunoreactivity for PD-L1. No in situ or minimally invasive cases recurred. IMA patients with pneumonic appearance had significantly worse recurrence-free survival (RFS) and overall survival (OS) ( p  < 0.001). Furthermore, IMA patients harboring KRAS mutations had worse RFS ( p  = 0.211). Multivariate analysis revealed that radiological pneumonic appearance was significantly associated with lower RFS ( p  < 0.003) and OS ( p  = 0.012). KRAS mutations served as an unfavorable status for RFS ( p  = 0.043). Conclusion Mucinous adenocarcinoma had a low frequency of targetable genetic variants and PD-L1 immunoreactivity; however, KRAS mutations were frequent. Pneumonic appearance on CT imaging and KRAS mutations were clinicopathological features associated with a worse prognosis.